MOL #61432
SP600125, anthra[1,9-cd]pyrazol-6(2H)-one; SN56, mouse septal neuron-derived cell line; TFA, trifluoroacetic acid.
Abstract:
Relaxin family peptide 3 receptors (RXFP3) are activated by H3-relaxin to inhibit forskolinstimulated cAMP accumulation and stimulate ERK1/2 phosphorylation. In this study we sought to identify novel signaling pathways coupled to RXFP3 and to investigate whether other members of the relaxin peptide family activated these pathways. Two patterns of signaling were observed in RXFP3-expressing Chinese hamster ovary (CHO)-K1 and human embryonic kidney (HEK)-293 cells (CHO-RXFP3 and HEK-RXFP3) and murine septal neuron, SN56, cell lines. The neuropeptide, relaxin-3 is the most recently identified member of the relaxin family of peptides and is expressed in the nucleus incertus, acting at relaxin-3 receptors (RXFP3) expressed at distal sites (Bathgate et al., 2002) . Relaxin-3 expression is upregulated in response to physical stress in rats, by a corticotrophin-releasing factor-dependent mechanism (Tanaka et al., 2005) , suggesting a role in mediating central stress responses. Relaxin-3 injection into the paraventricular nucleus of the hypothalamus or the 4th ventricle, increased food intake in rats (McGowan et al., 2007) , also indicating a role in appetite control acting via its cognate receptor, RXFP3. Development of ligands that target RXFP3 would potentially provide drugs for the treatment of obesity and anxiety disorders.
The term ligand-directed signaling (LDS, among other synonyms) was coined to describe the distinct efficacy profiles observed for different signaling pathways by individual ligands.
Typically, activated GPCRs (bound to their cognate ligand) fully activate all the signaling pathways coupled to the receptor. However, several studies have identified that many compounds classified as antagonists can activate their own spectrum of signaling pathways. Thus propranolol (traditionally classified as a β -adrenoceptor antagonist) acts at the β 1 -adrenoceptor as an inverse agonist for cAMP signaling but as a partial agonist for ERK1/2 signaling (Galandrin and Bouvier, 2006) , suggesting that the signaling assay selected as a read out of the response can bias the classification of a ligand. However, many GPCRs, including the α -and β 3 -MOL #61432
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To activate different signaling pathways, GPCRs may couple to multiple Gα-subunits (e.g. Gαs and Gαi/o),but signaling may also occur downstream of Gβγ-subunits or following β -arrestin recruitment and may not even involve G proteins. In addition, movement of GPCRs into or out of membrane rafts following ligand binding can switch the Gα-coupling and initiate additional signaling events providing another mechanism for GPCR coupling to multiple signal transduction pathways (reviewed in Chini and Parenti, 2004) .
RXFP3 is known to inhibit forskolin-stimulated cAMP accumulation and activates ERK1/2 in a Gαi/o-dependent manner (Liu et al., 2003; van der Westhuizen et al., 2007) and thus resembles many other GPCRs that couple to multiple signaling pathways when stimulated by their cognate ligand. RXFP3 was originally characterized by high affinity binding of H3 relaxin and little or no affinity for other members of the relaxin peptide family (Liu et al., 2003) . H3 relaxin potently inhibits forskolin-stimulated cAMP accumulation in RXFP3-expressing cells, consistent with competition binding data (Liu et al., 2003) . Furthermore, increases in GTPγS binding are only evident in cells stimulated with H3 relaxin or the B-chain of H3 relaxin (Liu et al., 2003) ,
suggesting that the other members of this peptide family do not strongly activate G proteindependent signaling pathways.
Despite the close homology between the relaxin family peptides, it was interesting that binding and signaling by other members of this peptide family was not observed at RXFP3. However, recent experience with GPCRs suggests that multiple signaling pathways should be monitored to determine whether a ligand has biased efficacy at a particular receptor. This study examined whether additional signaling pathways were activated by RXFP3 following stimulation with H3 MOL #61432 6 relaxin and determined whether other members of the relaxin peptide family could also activate signaling. CHO-RXFP3, HEK-RXFP3 and murine SN56 septal neuron-derived cells were characterized using binding and signaling assays. We identified, using reporter genes, two novel signaling pathways activated downstream of RXFP3, the NF-κB signaling pathway and pathways upstream of AP-1 transcription sites and demonstrated that many of the relaxin family peptides have affinity for RXFP3 and efficacy on AP-1 signaling. RXFP3 also has a binding site that recognizes H2 relaxin with a unique pharmacological profile compared to that described for RXFP1 and RXFP2. Thus we propose a novel site on RXFP3 that can interact with several relaxin peptides and that activation of the receptor by the various peptides results in activation of different signaling pathways.
MOL #61432 streptomycin and 0.5μg/ml fungizone. DMEM was supplemented with 10% (v/v) FBS, 4mM Lglutamine and antibiotics as above.
Whole cell radioligand binding assays -H2 relaxin and INSL5/H3 relaxin chimera were iodinated with Na 125 I using the chloramine T method (Sexton et al., 1986 (5, 10, 15, 30, 45, 60 min) in a shaking incubator. The plates were placed on ice and washed once with ice-cold PBS then acid-stripped using acid elution buffer (150mM sodium chloride, 50mM acetic acid, pH 2.5) for 10 min on ice. The acid was aspirated and the cells were washed three times with ice-cold Non-specific binding was defined in the presence of H3 relaxin (0.1µM) at each time point. The cells were washed, solubilised and counted as described for whole cell binding assays.
ERK phosphorylation assay -Cells (5×10 4 cells/well) were plated into 96-well plates and grown for 27h in complete DMEM or DMEM/Ham's F-12 medium and then serum-starved for 18h before experimentation and assayed for phospho-ERK1/2 (Surefire ® ERK kit) using a novel nonWestern blot-based proprietary technique that relies on the energy transfer-based AlphaScreen concept (Osmond et al., 2005) as described previously (van der Westhuizen et al., 2007) . Cells were treated for 2 to 30 min (time course assays) or 5 min (concentration-response curves) with relaxin family peptides at 37°C. As a positive control, cells were stimulated with foetal bovine serum (FBS: 10%; up to 30 min for time course assays or 5 min for concentration-response assays). Cell lysates were prepared and processed according to the manufacturer's protocol. In brief, a 5µl sample of processed cell lysate was transferred to a white 384-well Optiplate, and 6µl of a 1:1 mix of Protein A AlphaScreen donor and acceptor beads was added to each well. Plates were incubated for 2 h at 22°C in the dark. Samples were read on a Fusion-α microplate reader (PerkinElmer Life and Analytical Sciences) with excitation at 680nm and emission at 520-620nm.
Inhibition of forskolin-stimulated cAMP accumulation assay -Cells were plated and serum starved as described for the ERK1/2 assay described above. The cAMP AlphaScreen assay kit was used to measure the amount of cAMP generated by the cells upon stimulation with forskolin and its inhibition by relaxin family peptides as described previously (van der Westhuizen et al., 2007) . Briefly, DMEM was removed from the wells and replaced with stimulation buffer This article has not been copyedited and formatted. The final version may differ from this version. were used to identify novel signaling pathways downstream of RXFP3 (described in Halls et al., 2007) . Following reporter gene activation, the levels of SEAP in the culture medium are directly proportional to the changes in intracellular SEAP concentrations. The reporter gene SEAP is modified so it is heat stable, thus it is possible to eliminate endogenous alkaline phosphatase activity by heat treating the samples taken from the culture medium. A constitutively expressed β -galactosidase reporter gene was co-transfected with the SEAP reporter gene (1:1) to account for variation in transfection efficiencies between experiments.
This article has not been copyedited and formatted. The final version may differ from this version. Data and statistical analysis -cAMP accumulation assays were normalized against the response to forskolin (30μM) and ERK1/2 phosphorylation against the response to FBS (10% (v/v)).
SEAP reporter constructs were co-transfected at a 1:1 ratio with constitutively expressed β-galactosidase to account for the variation in transfection efficiency between experiments. SEAP activation was expressed as a % of β-galactosidase activation (8h post cell stimulation) and then normalized against the response to the positive control or the H3 relaxin response. All data are mean ± standard error of the mean (SEM) of n experiments as described in the figure legends.
This article has not been copyedited and formatted. The final version may differ from this version. Results:
CHO-RXFP3, HEK-RXFP3 and SN56 cells do not express RXFP1, RXFP2 or RXFP4 mRNA -
The profile of RXFPs expressed in CHO-RXFP3, HEK-RXFP3 and SN56 was examined by RT-PCR ( Fig. 1 ) to ensure that any effects observed were mediated solely through RXFP3 receptors.
RXFP3 mRNA was detected in CHO-RXFP3, HEK-RXFP3 and SN56 cells but not in CHO-K1, HEK293, HEK-RXFP1, HEK-RXFP2, CHO-RXFP4 or HEK-RXFP4 cells (Fig. 1A ). RXFP1
and RXFP2 mRNA expression ( 
Relaxin family peptides share regions of homology with the predicted binding region of H3
relaxin -Residues Arg8, Arg12, Ile15, Arg16 and Phe20 of H3 relaxin were recently shown to be important for H3 relaxin binding to RXFP3 (Kuei et al., 2007) . Alignment of H3 relaxin with H2 relaxin, porcine relaxin and human INSL3 ( (n=3; data not shown) in accord with the lack of endogenous expression of RXFP3 in these cells (Fig. 1) . These results suggest that H3 relaxin is a full agonist for ERK1/2 phosphorylation in cells that express RXFP3 and that H2 relaxin is a partial agonist at human, but not at mouse RXFP3.
H3 relaxin, H2 relaxin and porcine relaxin inhibit forskolin-stimulated cAMP accumulation in RXFP3-expressing cells -Since RXFP3 was previously shown to inhibit forskolin-stimulated
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Taken together, these results suggest that the RXFP3 expressing cells do not express RXFP1 or RXFP2 and that the observed inhibition of forskolin-stimulated cAMP accumulation occurs solely through RXFP3. . All reporter genes were tested with a positive control (forskolin, heat shock, ionomycin or FBS) confirming that they could be activated in these cells.
AP-1-SEAP and NF-κB-SEAP reporter genes are activated downstream of RXFP3 -
The preliminary reporter gene screening suggested that H3 relaxin activated signaling on the NF-κB pathway, whereas H2 relaxin and INSL3 did not (n=6, Supplementary Fig. 1 The preliminary reporter gene screening experiments also indicated that RXFP3 activated signaling in pathways leading to increased transcription from AP-1 sites ( Supplementary Fig. 1 ). (Fig. 4F) , although the potencies of H2 relaxin and H3 relaxin were lower than in CHO-RXFP3 and HEK-RXFP3 cells (Table 2) .
However, the relative potency and efficacy (i.e. H2 relaxin > H3 relaxin) was similar in all cell (Price et al., 1996; Roux and Blenis, 2004; Whitmarsh and Davis, 1996) . Therefore, (Fig. 7A ).
H2 relaxin-mediated AP-1 activation was strongly attenuated in CHO-RXFP3 cells pre-treated with RWJ67657 and SP600125 (Fig. 7B) , and PD98059 pre-treatment shifted the pEC 50 of the concentration-response curve to the right without decreasing the maximum response (Fig. 7B ).
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This suggested that both p38 MAPK and JNK play a dominant role in H2 relaxin-mediated AP-1 activation and that ERK has a minor role.
Porcine relaxin-activated transcription from AP-1 elements was blocked in CHO-RXFP3 cells pre-treated with SP600125 (Fig. 7C) , suggesting that the JNK signaling pathway was important for AP-1 activation. PD98059 or RWJ67657 pre-treatment shifted the pEC 50 of the porcine relaxin concentration-response curve to the right (Fig. 7C) suggesting that both p38 MAPK and ERK also influence transcription from AP-1 elements in CHO-RXFP3 cells. Together the results with relaxin family peptides suggested that combinations of pathways are required for maximum AP-1 reporter gene activation with some variation observed downstream of receptor activation by the different peptides.
Pre-treatment of HEK-RXFP3 cells with SP600125 completely blocked AP-1 activation at all concentrations of H3 relaxin tested (Fig. 7D ), suggesting that JNK was mandatory for H3
relaxin-mediated AP-1 activation. Pre-treatment of cells with either PD98059 or RWJ67657, shifted the H3 relaxin concentration-response curve to the right, suggesting that ERK and p38 MAPK pathways were also involved. H2 relaxin-mediated AP-1 activation was strongly attenuated in HEK-RXFP3 cells pre-treated with PD98059 and RWJ67657 (Fig. 7E ). This suggests that both p38 MAPK and ERK are important in H2 relaxin-mediated AP-1 activation in HEK-RXFP3 cells. In contrast, SP600125 pre-treatment did not alter the H2 relaxin concentration-response curve, suggesting that the JNK signaling pathway is not involved.
This article has not been copyedited and formatted. The final version may differ from this version. Porcine relaxin-mediated AP-1 activation was blocked by RWJ67657 and PD98059 in HEK-RXFP3 cells (Fig. 7F) , suggesting that p38 MAPK and ERK were important for AP-1 reporter gene activation. Porcine relaxin did not activate ERK1/2 in HEK-RXFP3 cells (Fig. 3D) , so it is unlikely that PD98059 produces this effect by blockade of MEK1/2. Since PD98059 also inhibits MEK5 at concentrations similar to those that inhibit MEK1/2 it is likely that the inhibition results from its effect on this pathway (38). In contrast, SP600125 treatment only partially abrogated the response (39.80±14.66%; Fig. 7F ).
Pre-treatment of SN56 cells with RWJ67657 completely blocked AP-1 activation at all concentrations of H3 relaxin tested (Fig. 7G ), suggesting that p38 MAPK was mandatory for H3
relaxin-mediated AP-1 activation. Pre-treatment with PD98059 or SP600125 partially blocked AP-1 activation, suggesting that ERK and JNK were also involved. Inhibition of one MAPK signaling pathway did not always completely inhibit the responses to relaxin family peptides, suggesting that in the absence of one MAPK pathway, other MAPK pathways may be able to compensate (Fig. 7G) . H2 relaxin-mediated AP-1 activation was blocked in SN56 cells pretreated with SP600125, PD98059 and RWJ67657 (Fig. 7H) , suggesting that ERK, JNK and p38 MAPK were all equally important for AP-1 activation in these cells. However, analysis was limited by the amount of peptides that could be synthesized, which did not allow full concentration-response curves to be constructed. (Fig. 8A , B and C), consistent with RXFP3 internalization. However, the number of cell surface binding sites was not reduced in cells exposed to H2 relaxin, porcine relaxin or INSL3 (all 0.1μM) (Fig. 8A , B and C), suggesting that these ligands do not cause RXFP3 internalization. In fact, H2 relaxin (but not porcine relaxin or INSL3) appeared to increase the number of cell surface binding sites in CHO-RXFP3 cells (Fig. 8A) but not significantly in HEK-RXFP3 or SN56 cells ( Fig. 8B and C ).
RXFP3 tagged with GFP 2 at its C-terminal tail was transiently expressed and used to visualize internalization in CHO-K1 and HEK293 cells following 60 min exposure to H3 relaxin, H2 relaxin, porcine relaxin or INSL3. Similar images were obtained in both cell lines, with only the images from HEK293 cells shown here. RXFP3-GFP 2 was expressed at the cell surface in unstimulated cells (Fig. 8D ) and treatment with vehicle (0.001% TFA) did not alter the distribution (Fig. 8D ). Following stimulation with H3 relaxin (10nM, 60 min), RXFP3−GFP 2 internalized into small vesicle-like structures (Fig. 8D ), but this did not occur in cells treated with H2 relaxin, porcine relaxin or INSL3 (Fig. 8D ). The images obtained by confocal microscopy were consistent with the results of the internalization binding studies (Fig. 8B) , suggesting that only H3 relaxin causes RXFP3 internalization. However, the apparent increase in 125 I-INSL5/H3 relaxin binding sites by H2 relaxin treatment of CHO-RXFP3 cells was not observed in the confocal imaging studies.
Discussion:
This article has not been copyedited and formatted. The final version may differ from this version. Baker and Hill, 2007; Kenakin, 2003) . This study demonstrates that Transcription from AP-1 sites can occur via JNK (Davis, 2000) , p38 MAPK (Roux and Blenis, 2004) , ERK1/2 (Whitmarsh and Davis, 1996) and/or ERK5 (Price et al., 1996) by regulation of c-Jun, c-Fos, MEF-2 and ATF2 (Marinissen et al., 1999; Price et al., 1996; Roux and Blenis, 2004 suggesting that ERK1/2 and JNK are important in stress responses (Shen et al., 2004) . H3 relaxin mRNA is also increased in the nucleus incertus following forced swim tests (Tanaka et al., 2005) and likely activates RXFP3 and MAPK signaling, although direct activation of MAPK in the brain by relaxin family peptides remains to be demonstrated.
The inhibitors selected to investigate the signaling pathways involved in AP-1 reporter gene activation downstream of RXFP3 were PD98059 (MEK1/2, MEK5), SP600125 (JNK1/2/3) and RWJ67657 (p38α/p38β MAPK) that have been tested for cross-reactivity against the other MAPKs ( Bain et al., 2007; Davies et al., 2000; Wadsworth et al., 1999) . PD98059 inhibits MEK1/2 (Alessi et al., 1995) but also MEK5 (Kamakura et al., 1999) . Tested, in vitro, against a panel of protein kinases, it did not inhibit JNK1, ERK2 or p38 MAPK at concentrations that inhibit MEK1/2/5 in cell-based assays (Davies et al., 2000) . SP600125 potently inhibits JNK1/2
This article has not been copyedited and formatted. The final version may differ from this version. and JNK3, but not p38 MAPK or ERK1/2, although it partially inhibits MEK1 (Bain et al., 2007) . RWJ67657 is a p38α/p38β MAPK inhibitor (Wadsworth et al., 1999) that is more potent than SB203580 and does not inhibit ERK2 (Bain et al., 2007; Wadsworth et al., 1999) .
SB203580 also inhibits JNK2/3 activity (40% inhibition) (Bain et al., 2007) , as may RWJ67657,
although this remains to be tested. In HEK293 cells stimulated with H2 relaxin, SP600125 had no effect on AP-1 activation, whereas in CHO-K1 cells, the response to H2 relaxin was blocked, Significant cross-talk also occurs between MAPKs at the level of protein kinase C (PKC), Raf/Rac and Src (Marinissen et al., 1999) . Since Src and PKC are activated upstream of ERK1/2 in CHO-RXFP3, HEK-RXFP3 and SN56 cells following stimulation with H3 relaxin (van der Westhuizen et al., 2007) , either pathway may be involved in increasing AP-1 transcription.
Activation of NF-κB may occur via PI3K (Brunet et al., 2001; Yuan and Yankner, 2000) , as seen for the δ -opioid receptor (Borlongan et al., 2004) , or via PKC as observed for the lysophosphatidic acid receptor (Shahrestanifar et al., 1999) . ERK5 also activates NF-κB (Pearson et al., 2001 ) and, although direct activation was not studied here, PD98059, inhibited porcine relaxin-mediated activation of AP-1 suggesting that ERK5 may be activated by RXFP3. Since
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